Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Manipal Health Enterprises Ltd / Equity Capital Markets

Manipal Health Enterprises Ltd (1217834D IN)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/manipal-health-enterprises-ltd" target="_blank" data-smartkarma-citation="entities:48013:1" rel="noopener">Manipal Health Enterprises</a>  (MHEL) raised around US$960m in its India IPO.</li>
<li>MHEL operates a pan‑India network of multispecialty hospitals delivering a range of care services, from outpatient services to complex tertiary and quaternary interventions</li>
<li>We have looked at the past performance in our previous note. In this note, we talk about the trading dynamics.</li>
</ul>



Manipal Health Enterprises  (MHEL) raised around US$960m in its India IPO.
MHEL operates a pan‑India network of multispecialty hospitals delivering a range of care services, from outpatient services to complex tertiary and quaternary interventions
We have looked at the past performance in our previous note. In this note, we talk about the trading dynamics.


Aequitas: Manipal Health IPO Trading - Lukewarm Demand

<ul>
<li>
<a href="https://www.smartkarma.com/entities/manipal-health-enterprises-ltd" target="_blank" data-smartkarma-citation="entities:48013:1" rel="noopener">Manipal Health Enterprises </a> (MHEL) is looking to raise up to US$960m in its upcoming India IPO.</li>
<li>MHEL operates a pan‑India network of multispecialty hospitals delivering a range of care services, from outpatient services to complex tertiary and quaternary interventions.</li>
<li>We have looked at the past performance in our previous note. In this note, we talk about the RHP updates and valuations.</li>
</ul>



Manipal Health Enterprises  (MHEL) is looking to raise up to US$960m in its upcoming India IPO.
MHEL operates a pan‑India network of multispecialty hospitals delivering a range of care services, from outpatient services to complex tertiary and quaternary interventions.
We have looked at the past performance in our previous note. In this note, we talk about the RHP updates and valuations.


Aequitas: Manipal Health IPO - RHP Updates and Thoughts on Valuations

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/raffles-medical-group-ltd" target="_blank" data-smartkarma-citation="entities:879:1" rel="noopener">Raffles Medical Group (RFMD SP)</a> ended 2025 with PATMI growth of 13% YoY to S$71M (25% YoY decline in 2024), driven by improved performance of hospital services and insurance businesses.</li>
<li>Hospital services division reported 4% YoY revenue growth to S$358M and 15% YoY profit growth to S$41M in 2025, supported by steady patient volumes, higher bill sizes, and operational efficiencies.</li>
<li>Balance sheet remained strong, with strong net cash position, providing flexibility to support strategic growth initiatives. The company is optimistic to remain profitable in 2026.</li>
</ul>



Raffles Medical Group (RFMD SP) ended 2025 with PATMI growth of 13% YoY to S$71M (25% YoY decline in 2024), driven by improved performance of hospital services and insurance businesses.
Hospital services division reported 4% YoY revenue growth to S$358M and 15% YoY profit growth to S$41M in 2025, supported by steady patient volumes, higher bill sizes, and operational efficiencies.
Balance sheet remained strong, with strong net cash position, providing flexibility to support strategic growth initiatives. The company is optimistic to remain profitable in 2026.


Raffles Medical (RFMD SP): Accelerated Earnings Growth in 2025; Positive Outlook

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ihh-healthcare-bhd" target="_blank" data-smartkarma-citation="entities:876:1" rel="noopener">IHH Healthcare (IHH MK)</a> delivered 1QFY25 revenue of RM 6.3B, up 6%, driven by sustained demand, favorable patient mix of more acute patient, and higher revenue per in-patient.</li>
<li>Hospital and Healthcare’s Q1FY25 EBITDA remained flat as higher revenues were offset by higher staff cost and start-up cost of newly opened Acibadem Kartal Hospital.</li>
<li>Turkiye &amp; Europe and Malaysia show strength. Margins remains under pressure in major markets.</li>
</ul>



IHH Healthcare (IHH MK) delivered 1QFY25 revenue of RM 6.3B, up 6%, driven by sustained demand, favorable patient mix of more acute patient, and higher revenue per in-patient.
Hospital and Healthcare’s Q1FY25 EBITDA remained flat as higher revenues were offset by higher staff cost and start-up cost of newly opened Acibadem Kartal Hospital.
Turkiye &amp; Europe and Malaysia show strength. Margins remains under pressure in major markets.


IHH Healthcare (IHH MK): Sustained Demand, Higher ARPOB Drive 1Q; Expansion Key for Future Growth

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ihh-healthcare-bhd" target="_blank" data-smartkarma-citation="entities:876:1" rel="noopener">IHH Healthcare (IHH MK)</a> reported 3Q24 revenue and EBITDA growth of 10% and 7%, YoY, respectively, after adjusting for hyperinflationary economy, driven by sustained demand and healthy case-mix.</li>
<li>Malaysia and Türkiye and Europe reported double-digit revenue growth, while EBITDA margin declined in both markets. Singapore is facing temporary margin pressure. India operation remained stable.</li>
<li>IHH has added ~1,000 beds in Malaysia and India, which should further drive growth. With growing healthcare needs both locally and globally, IHH Healthcare is confident of its trajectory.</li>
</ul>



IHH Healthcare (IHH MK) reported 3Q24 revenue and EBITDA growth of 10% and 7%, YoY, respectively, after adjusting for hyperinflationary economy, driven by sustained demand and healthy case-mix.
Malaysia and Türkiye and Europe reported double-digit revenue growth, while EBITDA margin declined in both markets. Singapore is facing temporary margin pressure. India operation remained stable.
IHH has added ~1,000 beds in Malaysia and India, which should further drive growth. With growing healthcare needs both locally and globally, IHH Healthcare is confident of its trajectory.


IHH Healthcare (IHH MK): Higher Patient Volume Drives Double-Digit Revenue Growth in 3Q24

Malaysia

IHH Healthcare is an international private healthcare group operating a network of over 80 hospitals and more than 140 facilities across 10 countries, including Malaysia, Singapore, Turkey, India, and Greater China. The company provides a comprehensive range of healthcare services, from primary and ambulatory to quaternary care, complemented by diagnostics, imaging, rehabilitation, telehealth, and home care. Headquartered in Kuala Lumpur, Malaysia, the company was founded in 2010.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IHH Healthcare (IHH SP)

Aequitas: Manipal Health IPO Trading - Lukewarm Demand

Manipal Health Enterprises (MHEL) raised around US$960m in its India IPO. In this note, we talk about the trading dynamics.

Sumeet Singh

Aequitas: Manipal Health IPO - RHP Updates and Thoughts on Valuations

Manipal Health Enterprises (MHEL) is looking to raise up to US$960m in its upcoming India IPO. In this note, we talk about the recent updates and...

Sumeet Singh

Raffles Medical (RFMD SP): Accelerated Earnings Growth in 2025; Positive Outlook

Raffles Medical saw 13% PATMI growth in 2025, driven by hospital and insurance businesses. Balance sheet remained strong, with net cash position....

Tina Banerjee

IHH Healthcare (IHH MK): Sustained Demand, Higher ARPOB Drive 1Q; Expansion Key for Future Growth

IHH Healthcare's 1QFY25 revenue rose 6% due to sustained demand and higher revenue per in-patient, but EBITDA remained flat with increased costs....

Tina Banerjee

IHH Healthcare (IHH MK): Higher Patient Volume Drives Double-Digit Revenue Growth in 3Q24

IHH Healthcare reports 3Q24 revenue and EBITDA growth of 10% and 7%, YoY, respectively. With growing healthcare needs both locally and globally,...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aequitas: Manipal Health IPO Trading - Lukewarm Demand

Manipal Health Enterprises (MHEL) raised around US$960m in its India IPO. In this note, we talk about the trading dynamics.

Sumeet Singh

Aequitas: Manipal Health IPO - RHP Updates and Thoughts on Valuations

Manipal Health Enterprises (MHEL) is looking to raise up to US$960m in its upcoming India IPO. In this note, we talk about the recent updates and...

Sumeet Singh

Raffles Medical (RFMD SP): Accelerated Earnings Growth in 2025; Positive Outlook

​Raffles Medical saw 13% PATMI growth in 2025, driven by hospital and insurance businesses. Balance sheet remained strong, with net cash position....

Tina Banerjee

IHH Healthcare (IHH MK): Sustained Demand, Higher ARPOB Drive 1Q; Expansion Key for Future Growth

​IHH Healthcare's 1QFY25 revenue rose 6% due to sustained demand and higher revenue per in-patient, but EBITDA remained flat with increased costs....

Tina Banerjee

IHH Healthcare (IHH MK): Higher Patient Volume Drives Double-Digit Revenue Growth in 3Q24

​IHH Healthcare reports 3Q24 revenue and EBITDA growth of 10% and 7%, YoY, respectively. With growing healthcare needs both locally and globally,...

Tina Banerjee

Raffles Medical saw 13% PATMI growth in 2025, driven by hospital and insurance businesses. Balance sheet remained strong, with net cash position....

IHH Healthcare's 1QFY25 revenue rose 6% due to sustained demand and higher revenue per in-patient, but EBITDA remained flat with increased costs....

IHH Healthcare reports 3Q24 revenue and EBITDA growth of 10% and 7%, YoY, respectively. With growing healthcare needs both locally and globally,...